Resproly
Latest round
- Series B
Last raised
- May 2022
Total raised
- $38M
Investors
- 11
About Resproly
, trading as Resproly, was established by Yongqi Chen, a former pharmaceutical expert at UK-based Vectura. The company has focused on the development of respiratory system drug delivery technologies and devices. Since its founding, it has received multiple awards in innovation and entrepreneurship competitions across Guangdong Province and nationally, including recognition at the Guangdong Medical Valley Open Day and the “Maker China” innovation contests.67 apiece for CNY 49 million, in a PIPE transaction. The company's main products include metered dose inhalation aerosols, inhalation powder aerosols, aerosol inhalers and nasal sprays. Nebulized inhaler is a drug-containing solution, emulsion or suspension placed in a special device, and the contents are released in the form of a mist with the help of a nebulizer system. The company's products are used in asthma, chronic obstructive pulmonary disease (COPD), diabetes, Parkinson's disease and other diseases. The company generates revenue through the development, manufacturing, and sale of inhalation drugs and associated delivery devices. Revenue also derives from contract production, pharmaceutical sales, and export activities in compliance with regulatory approvals.
Who invested in Resproly
11 investors across 3 rounds
See all investors in Resproly
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Resproly
Who invested in Resproly?
Resproly has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Resproly raised?
Resproly has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Resproly last raise money?
Resproly's most recent round on record is a Series B, in May 2022.
What does Resproly do?
, trading as Resproly, was established by Yongqi Chen, a former pharmaceutical expert at UK-based Vectura.
Where is Resproly headquartered?
Resproly is headquartered in Shenzhen, China.
Which VCs invest in companies like Resproly?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Resproly's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Resproly? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.